Progress in individualized treatment for EGFR-mutated advanced non-small cell lung cancer

Research output: Contribution to journalReview articlepeer-review

3 Citations (Scopus)


The identification of mutations in the epidermal growth factor receptor (EGFR) gene has revolutionized the treatment strategy for non-small cell lung cancer (NSCLC). The effectiveness of individualized treatment using EGFR tyrosine kinase inhibitors (TKIs) for EGFRmutated NSCLC has mainly been clarified in clinical trials within Japan, and EGFR-TKI monotherapy has been established as the standard first-line treatment for EGFR-mutated NSCLC. Since then, combination regimens involving EGFR-TKI and chemotherapy or anti-angiogenic agents have been developed. Regarding combinations, the NEJ009 study conducted in Japan showed a significant prolongation of progression-free survival and overall survival compared with gefitinib alone. The NEJ009 regimen may be a reasonable option for patients with good performance status in terms of risk-benefit balance. However, further investigation is warranted to improve clinical outcomes in EGFR-mutated NSCLC.

Original languageEnglish
Pages (from-to)266-272
Number of pages7
JournalProceedings of the Japan Academy Series B: Physical and Biological Sciences
Issue number7
Publication statusPublished - 2020


  • Chemotherapy
  • EGFR mutation
  • Lung cancer

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Physics and Astronomy(all)


Dive into the research topics of 'Progress in individualized treatment for EGFR-mutated advanced non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this